Wall Street brokerages expect Teva Pharmaceutical Industries Ltd (NYSE:TEVA) to report $4.23 billion in sales for the current quarter, Zacks reports. Eight analysts have provided estimates for Teva Pharmaceutical Industries’ earnings. The highest sales estimate is $4.35 billion and the lowest is $4.15 billion. Teva Pharmaceutical Industries reported sales of $4.53 billion in the same quarter last year, which would suggest a negative year over year growth rate of 6.6%. The business is scheduled to announce its next earnings report before the market opens on Thursday, November 7th.
On average, analysts expect that Teva Pharmaceutical Industries will report full-year sales of $17.18 billion for the current year, with estimates ranging from $17.02 billion to $17.36 billion. For the next fiscal year, analysts anticipate that the firm will post sales of $17.02 billion, with estimates ranging from $16.63 billion to $17.76 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that follow Teva Pharmaceutical Industries.
Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Wednesday, August 7th. The company reported $0.57 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.55 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 21.94% and a positive return on equity of 16.04%. The company had revenue of $4.34 billion for the quarter, compared to analysts’ expectations of $4.25 billion. During the same quarter last year, the company posted $0.78 earnings per share. The firm’s quarterly revenue was down 7.7% on a year-over-year basis.
Hedge funds have recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Teva Pharmaceutical Industries by 7.6% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 327,489 shares of the company’s stock worth $2,253,000 after purchasing an additional 23,000 shares during the period. Wedbush Securities Inc. boosted its stake in shares of Teva Pharmaceutical Industries by 32.6% during the 3rd quarter. Wedbush Securities Inc. now owns 42,347 shares of the company’s stock worth $291,000 after purchasing an additional 10,403 shares during the period. Envestnet Asset Management Inc. purchased a new position in shares of Teva Pharmaceutical Industries during the 3rd quarter worth about $82,000. G&S Capital LLC boosted its stake in shares of Teva Pharmaceutical Industries by 49.9% during the 3rd quarter. G&S Capital LLC now owns 6,012 shares of the company’s stock worth $41,000 after purchasing an additional 2,000 shares during the period. Finally, Commerzbank Aktiengesellschaft FI boosted its stake in shares of Teva Pharmaceutical Industries by 49.4% during the 3rd quarter. Commerzbank Aktiengesellschaft FI now owns 8,682,389 shares of the company’s stock worth $59,735,000 after purchasing an additional 2,869,139 shares during the period. Hedge funds and other institutional investors own 57.78% of the company’s stock.
TEVA stock traded down $0.27 on Tuesday, hitting $7.50. The company had a trading volume of 19,799,744 shares, compared to its average volume of 17,383,628. Teva Pharmaceutical Industries has a 12-month low of $6.07 and a 12-month high of $23.97. The company has a current ratio of 0.96, a quick ratio of 0.62 and a debt-to-equity ratio of 1.73. The stock’s 50-day simple moving average is $7.16 and its 200 day simple moving average is $9.59. The stock has a market cap of $8.48 billion, a price-to-earnings ratio of 2.68, a P/E/G ratio of 0.81 and a beta of 1.71.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Featured Article: How to Trade Using Analysts Ratings
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.